Mikhail  Eydelman net worth and biography

Mikhail Eydelman Biography and Net Worth

SVP of Vaxcyte
Mikhail is an accomplished legal executive who brings over 15 years of legal experience in multiple areas, including commercial agreements and partnerships, securities matters, business development, litigation, healthcare compliance and product launches. Most recently, Mikhail served as the General Counsel and Corporate Secretary at Sagent Pharmaceuticals, a commercial-stage pharmaceutical company, where he built the legal team and drove value across the organization. Previously, he was Assistant General Counsel for Integrated DNA Technologies, a supplier of nucleic acids acquired by Danaher Corporation, where he led the international legal function and supported the company’s strategic initiatives. Mikhail also held legal roles of increasing responsibility at Akorn, a publicly traded commercial-stage pharmaceutical company, where he supported overall business growth as the company quadrupled in size. Prior to that, he practiced law at the international law firms of Latham & Watkins, Allen & Overy and Bryan Cave. Mikhail earned his BA in Economics from Brandeis University and JD from New York University School of Law.

What is Mikhail Eydelman's net worth?

The estimated net worth of Mikhail Eydelman is at least $2.48 million as of December 5th, 2024. Mr. Eydelman owns 28,697 shares of Vaxcyte stock worth more than $2,483,151 as of December 21st. This net worth evaluation does not reflect any other investments that Mr. Eydelman may own. Additionally, Mr. Eydelman receives a salary of $684,620.00 as SVP at Vaxcyte. Learn More about Mikhail Eydelman's net worth.

How old is Mikhail Eydelman?

Mr. Eydelman is currently 42 years old. There are 7 older executives and no younger executives at Vaxcyte. The oldest executive at Vaxcyte is Mr. Paul W. Sauer M.B.A., Senior Vice President of Process Development & Manufacturing, who is 63 years old. Learn More on Mikhail Eydelman's age.

What is Mikhail Eydelman's salary?

As the SVP of Vaxcyte, Inc., Mr. Eydelman earns $684,620.00 per year. There are 2 executives that earn more than Mr. Eydelman. The highest earning executive at Vaxcyte is Mr. Grant E. Pickering M.B.A., Co-Founder, CEO & Director, who commands a salary of $1,130,000.00 per year. Learn More on Mikhail Eydelman's salary.

How do I contact Mikhail Eydelman?

The corporate mailing address for Mr. Eydelman and other Vaxcyte executives is 353 HATCH DRIVE, FOSTER CITY CA, 94404. Vaxcyte can also be reached via phone at 650-837-0111 and via email at [email protected]. Learn More on Mikhail Eydelman's contact information.

Has Mikhail Eydelman been buying or selling shares of Vaxcyte?

Over the course of the past ninety days, Mikhail Eydelman has sold $1,003,800.00 in shares of Vaxcyte stock. Most recently, Mikhail Eydelman sold 5,000 shares of the business's stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $91.49, for a transaction totalling $457,450.00. Following the completion of the sale, the senior vice president now directly owns 28,697 shares of the company's stock, valued at $2,625,488.53. Learn More on Mikhail Eydelman's trading history.

Who are Vaxcyte's active insiders?

Vaxcyte's insider roster includes Elvia Cowan (SVP), Mikhail Eydelman (SVP), Jeff Fairman (VP), Halley Gilbert (Director), Andrew Guggenhime (CFO), Heath Lukatch (Director), Grant Pickering (CEO), Paul Sauer (SVP), James Wassil (COO), Jim Wassil (COO), and Jane Wright-Mitchell (General Counsel). Learn More on Vaxcyte's active insiders.

Are insiders buying or selling shares of Vaxcyte?

In the last year, insiders at the sold shares 49 times. They sold a total of 427,456 shares worth more than $35,141,433.71. The most recent insider tranaction occured on December, 18th when CFO Andrew Guggenhime sold 8,000 shares worth more than $710,240.00. Insiders at Vaxcyte own 3.1% of the company. Learn More about insider trades at Vaxcyte.

Information on this page was last updated on 12/18/2024.

Mikhail Eydelman Insider Trading History at Vaxcyte

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/5/2024Sell5,000$91.49$457,450.0028,697View SEC Filing Icon  
10/7/2024Sell5,000$109.27$546,350.0028,623View SEC Filing Icon  
7/1/2024Sell1,667$76.37$127,308.7930,826View SEC Filing Icon  
6/3/2024Sell1,667$72.06$120,124.0231,161View SEC Filing Icon  
2/1/2024Sell1,667$73.87$123,141.2920,710View SEC Filing Icon  
1/2/2024Sell1,667$63.93$106,571.3120,710View SEC Filing Icon  
12/7/2023Sell10,000$56.50$565,000.0021,035View SEC Filing Icon  
10/2/2023Sell20,000$50.40$1,008,000.0020,487View SEC Filing Icon  
See Full Table

Mikhail Eydelman Buying and Selling Activity at Vaxcyte

This chart shows Mikhail Eydelman's buying and selling at Vaxcyte by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Vaxcyte Company Overview

Vaxcyte logo
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Read More

Today's Range

Now: $86.53
Low: $86.25
High: $88.90

50 Day Range

MA: $98.70
Low: $85.75
High: $117.93

2 Week Range

Now: $86.53
Low: $53.83
High: $121.06

Volume

3,859,357 shs

Average Volume

922,601 shs

Market Capitalization

$10.78 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.94